JB Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage … Read more
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) - Total Liabilities
Latest total liabilities as of September 2025: ₹9.07 Billion INR
Based on the latest financial reports, JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has total liabilities worth ₹9.07 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JB Chemicals & Pharmaceuticals Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how JB Chemicals & Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JB Chemicals & Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of JB Chemicals & Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ePlus inc
NASDAQ:PLUS
|
USA | $768.39 Million |
|
Reliance Worldwide Corporation Limited
PINK:RLLWF
|
USA | $820.88 Million |
|
Joulwatt Technology Co. Ltd. A
SHG:688141
|
China | CN¥3.01 Billion |
|
Photronics Inc
NASDAQ:PLAB
|
USA | $251.50 Million |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $57.07 Million |
|
Changzhou Fusion New Material Co. Ltd. A
SHG:688503
|
China | CN¥4.71 Billion |
|
Dynex Capital Inc
NYSE:DX
|
USA | $12.20 Billion |
|
Aecc Aero Engine Control Co Ltd
SHE:000738
|
China | CN¥3.17 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down JB Chemicals & Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.15 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JB Chemicals & Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JB Chemicals & Pharmaceuticals Limited (2005–2025)
The table below shows the annual total liabilities of JB Chemicals & Pharmaceuticals Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹8.40 Billion | -21.51% |
| 2024-03-31 | ₹10.71 Billion | -0.25% |
| 2023-03-31 | ₹10.74 Billion | +129.00% |
| 2022-03-31 | ₹4.69 Billion | +10.39% |
| 2021-03-31 | ₹4.25 Billion | +13.08% |
| 2020-03-31 | ₹3.76 Billion | +21.91% |
| 2019-03-31 | ₹3.08 Billion | -3.89% |
| 2018-03-31 | ₹3.21 Billion | +4.01% |
| 2017-03-31 | ₹3.08 Billion | -33.30% |
| 2016-03-31 | ₹4.62 Billion | -6.16% |
| 2015-03-31 | ₹4.92 Billion | +59.76% |
| 2014-03-31 | ₹3.08 Billion | +10.10% |
| 2013-03-31 | ₹2.80 Billion | +22.86% |
| 2012-03-31 | ₹2.28 Billion | -25.98% |
| 2011-03-31 | ₹3.08 Billion | +14.50% |
| 2010-03-31 | ₹2.69 Billion | -3.09% |
| 2009-03-31 | ₹2.77 Billion | -3.77% |
| 2008-03-31 | ₹2.88 Billion | -1.89% |
| 2007-03-31 | ₹2.94 Billion | +68.00% |
| 2006-03-31 | ₹1.75 Billion | +37.57% |
| 2005-03-31 | ₹1.27 Billion | -- |